Dose rate in the highest irradiation area of the rectum correlates with late rectal complications in patients treated with high-dose-rate computed tomography-based image-guided brachytherapy for cervical cancer.


Journal

Journal of radiation research
ISSN: 1349-9157
Titre abrégé: J Radiat Res
Pays: England
ID NLM: 0376611

Informations de publication

Date de publication:
12 May 2021
Historique:
received: 20 01 2021
revised: 21 02 2021
pubmed: 19 4 2021
medline: 26 11 2021
entrez: 18 4 2021
Statut: ppublish

Résumé

The purpose of this study was to evaluate the effect of dose rate to the rectum on late rectal complications in patients treated with computed tomography (CT)-based image-guided brachytherapy (IGBT) for cervical cancer. The subjects were 142 patients with cervical cancer who underwent Ir-192 high-dose-rate (HDR)-IGBT between March 2012 and January 2018. The dose rate to the rectum was calculated using in-house software. The minimum, mean and maximum effective dose rate (EDR) was calculated for voxels of the rectal volume covered by cumulative doses >D0.1cc, >D2cc, and > D5cc. The average EDR of three to four brachytherapy sessions was calculated (EDR for patients; EDRp). The total dose of the rectum was calculated as the biologically equivalent dose in 2-Gy fractions (EQD2). The associations between EDRp for D0.1cc, D2cc, and D5cc and the respective rectal EQD2 values with late rectal complications were then analyzed. The median follow-up period was 40 months. Patients with rectal complications of ≥Grade 1 received a significantly higher mean EDRp for D0.1cc-5cc and had a greater EQD2 for D0.1cc-5cc. Multivariate analysis was performed using the mean EDRp for D2cc, EQD2 for D2cc, heavy smoking and BMI. Of these four variables, mean EDRp for D2cc (HR = 3.38, p = 0.004) and EQD2 for D2cc (HR = 2.59, p = 0.045) emerged as independent predictors for late rectal complications. In conclusion, mean EDRp and EQD2 were associated with late rectal complications in patients treated with HDR CT-based IGBT for cervical cancer.

Identifiants

pubmed: 33866361
pii: 6232580
doi: 10.1093/jrr/rrab023
pmc: PMC8127676
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

494-501

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology.

Références

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):653-7
pubmed: 21345618
Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1403-14
pubmed: 1938548
Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):839-45
pubmed: 11172968
Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):e353-62
pubmed: 22483697
J Radiat Res. 2019 Mar 1;60(2):264-269
pubmed: 30649485
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):250-5
pubmed: 21183288
Radiother Oncol. 2016 Sep;120(3):412-419
pubmed: 27396811
Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):758-64
pubmed: 19836150
Int J Radiat Oncol Biol Phys. 1993 Feb 15;25(3):405-12
pubmed: 8436517
J Clin Oncol. 2002 Sep 1;20(17):3651-7
pubmed: 12202666
Gynecol Oncol. 2019 Mar;152(3):540-547
pubmed: 30665615
Phys Med Biol. 2017 Feb 01;62(4):1613-1631
pubmed: 28145285
Med Phys. 2004 Mar;31(3):633-74
pubmed: 15070264
J Radiat Res. 2010;51(2):173-9
pubmed: 20339254
Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):850-7
pubmed: 11849811
Radiother Oncol. 2012 Jun;103(3):305-13
pubmed: 22633469
J Radiat Res. 2017 May 1;58(3):341-350
pubmed: 27837120
CA Cancer J Clin. 2019 Sep;69(5):386-401
pubmed: 31361333
Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):953-60
pubmed: 8083096
Int J Radiat Oncol Biol Phys. 2011 Feb 1;79(2):356-62
pubmed: 20385450
Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):491-8
pubmed: 17331668
Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):111-9
pubmed: 23849695
Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1329-34
pubmed: 18439763

Auteurs

Fumiaki Isohashi (F)

Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan.

Yuichi Akino (Y)

Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan.

Yuri Matsumoto (Y)

Department of Gynecology and Obstetrics, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan.

Osamu Suzuki (O)

Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan.

Yuji Seo (Y)

Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan.

Keisuke Tamari (K)

Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan.

Iori Sumida (I)

Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan.

Kenjiro Sawada (K)

Department of Gynecology and Obstetrics, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan.

Yutaka Ueda (Y)

Department of Gynecology and Obstetrics, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan.

Eiji Kobayashi (E)

Department of Gynecology and Obstetrics, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan.

Takuji Tomimatsu (T)

Department of Gynecology and Obstetrics, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan.

Erina Nakanishi (E)

Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan.

Takahisa Nishi (T)

Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan.
Department of Radiation Oncology, Osaka International Cancer Institute, Osaka, 541-8567, Japan.

Tadashi Kimura (T)

Department of Gynecology and Obstetrics, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan.

Kazuhiko Ogawa (K)

Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH